Gardasil (HPV vaccine) Information Center.
Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions.
CONCLUSIONS: Polysorbate 80 is a ubiquitously used solubilizing agent that can cause severe nonimmunologic anaphylactoid reactions.
PMID: 16400901 [PubMed - indexed for MEDLINE]
From ABC News' Chief Medical Editor Dr. Timothy Johnson:
Today's issue of the Journal of the American Medical Association (JAMA) contains two articles - and an excellent editorial - addressing the question of whether the benefits of the Gardasil vaccine outweigh its risks. The vaccine is designed to prevent infection by two strains of the HPV (Human Papilloma Virus); these strains are said to account for about 70% of cervical cancer cases. The vaccine is now recommended for 11-12 year old girls before they become sexually active.(READ THIS) [For the first time in my career, I cannot recommend a vaccine for its intended population -- in this case, young girls. Therefore I am going to say that any parent considering this vaccine for their daughter should read the editorial in JAMA and then talk to their doctor before deciding].
What the Amercian Medical association states about Gardasil; you might want to read THAT!
Vol. 302 No. 7, August 19, 2009
Sodium borate; (borax) in Gardasil.
CDC Report Stirs Controversy For Merck's Gardasil Vaccine.
---------------------------
OBGYN Questions HPV Vaccine Gardasil.
Excerpt:
Editorial Office
Obstetrics and Gynecology
The American College of Obstetricians and Gynecologists
409 12th Street, SW
Washington, DC 20024-2188
I am writing in response to the recent Committee Opinion 344 Published in the September issue of Obstetrics and Gynecology. I have several concerns regarding Gardasil.
First, the Gardasil's product insert states their endpoint is the prevention of "High Grade Disease", this encompasses CIN II-III and adenocarcinoma in situ (AIS) which are "immediate and necessary precursors" for squamous cell and adenocarcinoma of the cervix.1 The MAXIMUM median follow up in any of their studies is FOUR years. However, the time course from CIN III to invasive cancer averages between 8.1 to 12.6 years.2 Claiming this vaccine prevents cervical cancer, with the longest median study subject being 4 years, is inappropriate.
The vaccine only "protects" against 4 high risk HPV subtypes. We are currently screening for 15 "high risk" HPV subtypes. This may lead to an increase in infection with other and possibly more aggressive subtypes.
According to ACOG, "The vast majority of women clear or suppress HPV to levels not associated with CIN II or III and for most women this occurs promptly. The duration of HPV positivity (which is directly related to the likelihood of developing a high grade lesion or cervical cancer) is shorter, and the likelihood of clearance is higher, in younger women."3 Seventy percent of women clear the virus spontaneously after 18 months and 90 % clear the virus after 2 years.4 Vaccinating children against HPV with a vaccine that is of unknown duration of efficacy may only postpone their exposure to an age which they are less likely clear the infection on their own and be subject to more severe disease, including the cervical cancer which the vaccine is supposedly preventing. This would require an unknown number of boosters and is a setup for complacency in the older population that is a recipe for disaster.
The likelihood for regression to a normal pap from CIN II with expectant management is 40%.5 This beats Gardasil's reduction of CIN II-III of only 39% in the "general population impact group" which is where most people would currently fall.6 This includes "all subjects who received at least one vaccination (regardless of baseline HPV status at Day 1."7 Since ACOG does not currently recommend serologic testing for HPV before vaccination this will be the endpoint from here out. In this case, "first do no harm" rules.
---
I have personally witnessed the devastation caused by severe vaccine reaction, including patients, their children, nurses and my own family. To proceed with mass vaccination against this embellished "threat" is premature.
Clayton Young, M.D., F.A.C.O.G.
Cc: NVIC, AAPS, PROVE
Read full article here:
-------------------------
Gardasil - the Cervical Cancer Vaccine? FDA Approval Not Based On Actual Cancer Prevention.
Questions on Efficacy Cloud a Cancer Vaccine.
Original source. Cancer Monthly.
FDA Page on Gardasil; (The Ultimate continued Cover-up, AND LIES page)!